Past, present and future of hemophilia: a narrative review

Orphanet Journal of Rare Diseases

Pier Mannuccio Mannucci¹  Massimo Franchini² 

[1] Scientific Direction, IRCCS Cà Granda Foundation Maggiore Policlinico Hospital, Via Pace, 9, 20122, Milan, Italy;Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Milan, Italy

关键词: Gene therapy;    Recombinant factor concentrates;    Plasma-derived factor concentrates;    FIX;    FVIII;   

Others  :  864427
DOI  :  10.1186/1750-1172-7-24

 received in 2011-01-14, accepted in 2012-03-29,  发布年份 2012

【 摘 要 】

Over the past forty years the availability of coagulation factor replacement therapy has greatly contributed to the improved care of people with hemophilia. Following the blood-borne viral infections in the late 1970s and early 1980, caused by coagulation factor concentrates manufactured using non-virally inactivated pooled plasma, the need for safer treatment became crucial to the hemophilia community. The introduction of virus inactivated plasma-derived coagulation factors and then of recombinant products has revolutionized the care of these people. These therapeutic weapons have improved their quality of life and that of their families and permitted home treatment, i.e., factor replacement therapy at regular intervals in order to prevent both bleeding and the resultant joint damage (i.e. primary prophylaxis). Accordingly, a near normal lifestyle and life-expectancy have been achieved. The main current problem in hemophilia is the onset of alloantibodies inactivating the infused coagulation factor, even though immune tolerance regimens based on long-term daily injections of large dosages of coagulation factors are able to eradicate inhibitors in approximately two-thirds of affected patients. In addition availability of products that bypass the intrinsic coagulation defects have dramatically improved the management of this complication. The major challenges of current treatment regimens, such the short half life of hemophilia therapeutics with need for frequent intravenous injections, encourage the current efforts to produce coagulation factors with more prolonged bioavailability. Finally, intensive research is devoted to gene transfer therapy, the only way to ultimately obtain cure in hemophilia.

【 授权许可】

   
2012 Franchini and Mannucci; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Mannucci PM, Tuddenham EGD: The hemophiliac – from royal genes to gene therapy. N Engl J Med 2001, 344:1773-1779.
• [2]Bolton-Maggs PH, Pasi KJ: Hemophilias A and B. Lancet 2003, 361:1801-1809.
• [3]Hoyer LH, Hemophilia A: N Engl J Med. 1994, 330:38-47.
• [4]Otto JC: An account of an hemorrhagic disposition existing in certain families. Med Repos 1803, 6:1-4.
• [5]Rogaev EI, Grigorenko AP, Faskhutdinova G, Kittler EL, Moliaka YK: Genotype analysis identifies the cause of the "royal disease". Science 2009, 326:817.
• [6]Stevens RF: The history of haemophilia in the royal families of Europe. Br J Haematol 1999, 105:25-32.
• [7]Biggs R, Douglas AS, Macfarlane RG, Dacie JV, Pitney WR, Merskey C, O'Brien JR: Christmas disease: a condition previously mistaken for haemophilia. Br Med J 1952, ii:1378-1382.
• [8]Mannucci PM: Back to the future: a recent history of haemophilia treatment. Haemophilia 2008, 14(Suppl. 3):10-18.
• [9]Mannucci PM: Hemophilia and related bleeding disorders: a story of dismay and success. Hematology Am Soc Hematol Educ Program 2002, 1:1-9.
• [10]Nilsson IM: Experience with prophylaxis in Sweden. Semin Hematol 1993, 30(3 Suppl 2):16-19.
• [11]Mannucci PM: Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia 2000, 6(Suppl 1):60-67.
• [12]Mannucci PM: Hemophilia: treatment options on the twenty-first century. J Thromb Haemost 2005, 1:1349-1355.
• [13]White GC, McMillan CW, Kingdon HS, Shoemaker CB: Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989, 320:166-170.
• [14]Llewelyn CA, Hewitt PE, Knight RS, et al.: Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004, 363(9407):417-421.
• [15]Pipe SW: Recombinant clotting factors. Thromb Haemost 2008, 99:840-850.
• [16]Franchini M, Lippi G: Recombinant factor VIII concentrates. Semin Thromb Hemost 2010, 36:493-497.
• [17]Franchini M, Tagliaferri A, Mannucci PM: The management of hemophilia in elderly patients. Clin Interv Aging 2007, 2:361-368.
• [18]Franchini M, Mannucci PM: Co-morbidities and quality of life in elderly persons with haemophilia. Br J Haematol 2010, 148:522-533.
• [19]Tagliaferri A, Rivolta GF, Iorio A, Oliovecchio E, Mancuso ME, Morfini M, Rocino A, Mazzucconi MG, Franchini M: Italian Association of Hemophilia Centers: Mortality and causes of death in Italian persons with haemophilia, 1990–2007. Haemophilia 2010, 16:437-446.
• [20]Franchini M, Mannucci PM: Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol 2011. in press
• [21]Astermark J, Santagostino E, Keith Hoots W: Clinical issues in inhibitors. Haemophilia 2010, 16(Suppl 5):54-60.
• [22]Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E, FENOC Study Group: A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007, 109:546-551.
• [23]Knight C, Danø AM, Kennedy-Martin T: Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors. Adv Ther 2009, 26:68-88.
• [24]Treur MJ, McCracken F, Heeg B, Joshi AV, Botteman MF, De Charro F, Van Hout B: Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression. Haemophilia 2009, 15:420-436.
• [25]Iorio A, Matino D, D’Amico R, Makris M: Recombinant factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with hemopphilia and inhibitors. Cochrane Database Syst Rev 2010, 8:CD004449.
• [26]Astermark J: Inhibitor development: patient-determined risk factors. Haemophilia 2009, 5:263-265.
• [27]Chambost H: Assessing risk factors: prevention of inhibitors in haemophilia. Haemophilia 2010, 16(Suppl 2):10-15.
• [28]Aledort LM: Is the incidence and prevalence of inhibitor greater with recombinant products? Yes. J Thromb Haemost 2004, 2:861-862.
• [29]Ettingshausen CE, Kreuz W: Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006, 12(suppl 6):102-106.
• [30]Goudemand J: Inhibtor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates. Haemophilia 2007, 13(Suppl 5):47-51.
• [31]Franchini M, Lippi G: VWF-containing FVIII concentrates and inhibitors in hemophilia A: a critical literature review. Thromb Haemost 2010, 104:931-940.
• [32]Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, Borel-Derlon A, Claeyssens S, Laurian Y, Calvez T: FVIII-LFB and Recombinant FVIII study groups: Influence of the type of factor VIII concentrate on the incidence of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. Blood 2006, 107:46-51.
• [33]Chalmers EA, Brown SA, Keeling D, Liesner R, Richards M, Stirling D, Thomas A, Vidler V, Williams MD, Young D: Paediatric Working Party of UKHCDO: Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007, 13:149-155.
• [34]Gouw SC, van der Bom JG, Marijke Van Den Berg H: Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007, 109:4648-4654.
• [35]Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, Young G, Bidlingmaier C, Brandao LR, Ettingshausen CE, Gringeri A, Kenet G, Knöfler R, Kreuz W, Kurnik K, Manner D, Santagostino E, Mannucci PM, Nowak-Göttl U: Rate of inhibitor development in previously-untreated hemophilia a patients treated with plasma-derived or recombinant factor VIII concentrates, A systematic review. J Thromb Haemost 2010, 8:1256-1265.
• [36]Mannucci PM, Gringeri A, Peyvandi F, Santagostino E: Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007, 13(Suppl 5):65-68.
• [37]Donadel-Claeyssens S: Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 2006, 12:124-127.
• [38]Chambost H, Meunier S: Relevance of early paediatric care for boys with severe haemophilia. Arch Pediatr 2006, 13:1423-1430.
• [39]Tagariello G, Zanotto D, Radossi P, Sartori R, Belvini D, Salviato R: In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates. Am J Hematol 2007, 82:460-462.
• [40]Salvagno GL, Astermark J, Ekman M, Franchini M, Guidi GC, Lippi G, Poli G, Berntorp E: Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia 2007, 13:51-56.
• [41]Kaveri S, Mannucci PM, Kurth MH, Ewing N, Kessler CM, Nugent DJ, Gomperts ED: Von Willebrand factor: what is its role in the immune response in haemophilia? Haemophilia 2010. Epub ahead of print
• [42]Mannucci PM: Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better. Blood Transfus 2010, 8:288-291.
• [43]Santagostino E, Mancuso ME: Venous access in haemophilic children: choice and management. Haemophilia 2010, 16(Suppl 1):20-24.
• [44]Mancuso ME, Berardinelli L: Arteriovenous fistula as stable venous access in children with severe haemophilia. Haemophilia 2010, 16(Suppl 1):25-28.
• [45]Santagostino E, Gringeri A, Berardinelli L, Beretta C, Muc,a-Perja M, Mannucci PM: Long-term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study. Br J Haematol 2003, 123:502-506.
• [46]Mancuso ME, Berardinelli L, Beretta C, Raiteri M, Pozzoli E, Santagostino E: Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up. Haematologica 2009, 94:687-692.
• [47]McCarthy WJ, Valentino LA, Bonilla AS, Goncharova I, Taylor A, Pooley TA, Jacobs CE: Arteriovenous fistola for long-term venous access for boys with hemophilia. J Vasc Surg 2007, 45:986-990.
• [48]Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL: Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357:535-544.
• [49]Valentino LA: Secondary prophylaxis therapy: what are benefits, limitations and unknown? Haemophilia 2004, 10:147-157.
• [50]Tagliaferri A: Awaiting evidence-based recommendations on prophylaxis in adult patients. Haemophilia 2010, 16:955-956.
• [51]Valentino LA: Controversies regarding the prophylactic management of adults with severe haemophilia A. Haemophilia 2009, 15(Suppl 2):5-18.
• [52]Coppola A, Tagliaferri A, Franchini M: The management of cardiovascular diseases in patients with hemophilia. Semin Thromb Hemost 2010, 36:91-102.
• [53]Mannucci PM, Mauser-Bunschoten EP: Cardiovascular disease in haemophilia patients: a contemporary issue. Haemophilia 2010, 16(Suppl 3):58-66.
• [54]Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP: How I treat age-related morbidities in elderly persons with hemophilia. Blood 2009, 114:5256-5263.
• [55]Franchini M, Lippi G, Montagnana M, Targher G, Zaffanello M, Salvagno GL, Rivolta GF, Perna CD, Tagliaferri A: Hemophilia and cancer: a new challenge for hemophilia centers. Cancer Treat Rev 2009, 35:374-377.
• [56]Dolan G, Hermans C, Klamroth R, Madhok R, Schutgens RE, Spengler U: Challenges and controversies in haemophilia care in adulthood. Haemophilia 2009, 15(Suppl 1):20-27.
• [57]Konkle BA, Kessler C, Aledort L, Andersen J, Fogarty P, Kouides P, Quon D, Ragni M, Zakarija A, Ewenstein B: Emerging clinical concerns in the ageing haemophilia patient. Haemophilia 2009, 15:1197-1209.
• [58]Youjin S, Jun Y: The treatment of hemophilia: from protein replacememt to AAV-mediated gene therapy. Biotechnol Lett 2009, 31:321-328.
• [59]Pfeifer A, Verma IM: Gene therapy: promises and problems. Annu Rev Genomics Hum Genet 2001, 2:177-211.
• [60]Kelley K, Verma I, Pierce GF: Gene therapy: reality or myth for the global bleeding disorders community? Haemophilia 2002, 8:261-267.
• [61]Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA: Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000, 24:257-261.
• [62]Powell JS, Ragni MV, White GC, Lusher JM, Hillman-Wiseman C, Moon TE, Cole V, Ramanathan-Girish S, Roehl H, Sajjadi N, Jolly DJ, Hurst D: Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003, 102:2038-2045.
• [63]Roth DA, Tawa NE, O_Brien JM, Treco DA, Selden RF: Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001, 344:1735-1742.
• [64]Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006, 12:342-347.
• [65]High KA: Update on progress and hurdles in novel genetic therapies for hemophilia. Hematology Am Soc Hematol Educ Program 2007, 466-472.
• [66]Yarovoi HV, Kufrin D, Eslin DE, Thornton MA, Haberichter SL, Shi Q, Zhu H, Camire R, Fakharzadeh SS, Kowalska MA, Wilcox DA, Sachais BS, Montgomery RR, Poncz M: Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood 2003, 102:4006-4013.
• [67]Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC, Desai D, Morateck PA, Gorski J, Montgomery RR: Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest 2006, 116:1974-1982.
• [68]Saenko EL, Ananyeva NM, Shima M, Hauser CA, Pipe SW: The future of recombinant coagulation factors. J Thromb Haemost 2003, 1:922-930.
• [69]Batorova A, High KA, Gringeri A: Special lectures in hemophilia management. Haemophilia 2010, 16(Suppl. 5):22-28.
• [70]Saenko EL, Pipe SW: Strategies towards a longer acting factor VIII. Haemophilia 2006, 12:42-51.
• [71]Di Minno G, Cerbone AM, Coppola A, Cimino E, Di Capua M, Pamparana F, Tufano A, Di Minno MN: Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue. Haemophilia 2010, 16(Suppl 1):2-6.
• [72]Spira J, Plyusch OP, Andreeva TA, Andreev Y: Prolonged bleeding free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 2006, 108:3668-3673.
• [73]Sen P, Ghosh S, Ezban M, Pendurthi UR, Vijaya Mohan Rao L: Effect of glycoPEGylation on factor VIIa binding and internationalization. Haemophilia 2010, 16:339-348.
• [74]Spira J, Plyushch O, Zozulya N, Yatuv R, Dayan I, Bleicher A, Robinson M, Baru M: Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII–an open label, exploratory, cross-over, phase I/II study. Haemophilia 2010, 16:910-918.
• [75]Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S: Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009, 102:634-644.
• [76]Schulte S, Weimer T, Wormsbaeche W, Kronthaler U, Groener A, Lang W, Liebing U: Prolonged in-vivo half-life of FVIIa by fusion to albumin. Blood 2007, 110:924a. abstract
• [77]Mahlangu J, Andreeva TA, Macfarlane D, Reding MT, Walsh C, Ritchie B, Ewing N, Kessler CM, Kempton C, Libby E, Zozulya N, Shapiro AD, St-Louis J, Warrier I, Keith Hoots W, Gruppo RA, Mueksch JN: A phase II open-label study evaluating hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI-1) in hemophilia A patients with alloantibody inhibitors directed against human FVIII. Blood 2007, 110:241a. abstract
• [78]Mannucci PM, Roberts HR: Uncertain times for research on hemophilia and allied disorders. J Thromb Haemost 2005, 3:423.